Incepta Pharmaceuticals Ltd. is the second-largest pharmaceutical company in Bangladesh. Among the top 5 manufacturing companies in the country, Incepta is considered to be the fastest-growing one. Incepta's mission is to provide quality healthcare products and services for people, with a stern focus on innovation and diversification. 

Incepta offers 1100 products as of 2020, with impressive manufacturing facilities owing to the two top-notch plants at Zirabo and Dhamrai. Both the plants boast state-of-the-art technology, with different manufacturing buildings for cephalosporin and lyophilized products. 

In terms of oncological products, Incepta has an impressive repertoire. Here are some of the products that Incepta offers in the oncology therapeutic group:

1. Erlocent: Used to treat non-small cell lung cancer and pancreatic cancer
2. Crizocent: Prescribed for treating metastatic non-small cell lung cancer 
3. Geficent: Used for the first-line treatment of patients with metastatic non-small cell lung cancer
4. Ibrucent: Prescribed for treating mantle cell lymphoma and chronic lymphocytic leukemia
5. Imacent: Prescribed to treat Philadelphia chromosome-positive chronic myeloid leukemia, refractory Ph+ acute lymphoblastic leukemia, etc.
6. Lapacent: Used to treat advanced or metastatic breast cancer
7. Lenvacent: Indicated for patients with locally recurrent or metastatic differentiated thyroid cancer (DTC)
8. Osicent: Used to treat mutation-positive non-small cell lung cancer
9. Palbocent: Used to treat metastatic breast cancer
10. Soracent: Prescribed for treating unresectable hepatocellular carcinoma, advanced renal cell carcinoma, etc.